Telomir Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) on January 8, 2026. The report addresses a regulatory compliance issue regarding the company's failure to hold its annual meeting of shareholders within the required timeframe.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing compliance matters.
Material Changes and Events
- Nasdaq Non-Compliance Notice: On January 8, 2026, the company received a notice from Nasdaq indicating non-compliance with Listing Rule 5620(a), which mandates an annual shareholder meeting within twelve months of the fiscal year-end.
- Reason for Delay: The company had planned to hold its annual meeting on December 30, 2025, but the meeting was delayed because the preliminary proxy statement (Schedule 14A), submitted on November 20, 2025, remained under review by the SEC.
- Current Status: The notice does not result in immediate delisting, and trading of the company's common stock on the Nasdaq Capital Market continues unaffected.
Outlook, Management Commentary, and Risks
- Compliance Plan: The company has until February 23, 2026, to submit a plan to regain compliance. Management intends to submit this plan timely and take all necessary steps to cure the deficiency.
- Future Actions: Following the completion of the SEC review process, the company expects to promptly hold its annual meeting.
- Risks: Forward-looking statements in the filing highlight risks related to the company's ability to submit a satisfactory compliance plan to Nasdaq and its ability to successfully hold the annual meeting.
Key Facts for Investor Verification
- Verify the status of the SEC review of the company's Schedule 14A proxy statement.
- Monitor the submission of the compliance plan to Nasdaq by the February 23, 2026 deadline.
- Confirm the scheduled date for the annual meeting of shareholders once the SEC review is complete.
- Review subsequent filings for any updates regarding the acceptance of the compliance plan by Nasdaq.